Pancreatic cancer pill that doubled survival may get Canada clinical trial
Medical experts are optimistic about a new experimental drug, daraxonrasib, which has shown potential to double survival rates in pancreatic cancer patients. Canadian oncologists are working to bring clinical trials to the country to provide early access to the treatment.
Why it matters
Pancreatic cancer is notoriously difficult to treat, and a breakthrough that significantly extends survival could represent a major shift in oncology outcomes.
The head of pancreatic cancer at Princess Margaret Cancer Centre says she hopes clinical trials for a pill that could double survival time will soon be open to Canadian patients.
The article reports on medical research and clinical trial efforts using objective, science-based language.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in